Figures

Figure 1: Structure of the decision model describing the pathways of patients with breast cancer.


Figure 2: Mean avoided cases of breast cancer with Raloxifene

Figure 3: Mean cost per patient of breast cancer by age


Figure 4: Mean QALY loss per patient of breast cancer by age

Figure 5:


Figure 5: The contribution of breast cancer benefits to the total QALYs gained for Raloxifene. "Single-risk" population

Figure 6:

The contribution of breast cancer, CVD and fracture benefits to the total QALYs gained for Raloxifene. "Single-risk" population.

**Figure 7: The cost-effectiveness acceptability curves for Raloxifene, women aged 50yrs.**

CEACs for Raloxifene, 50yr olds. "Single-risk" population.

Note: WTP is "willingness to pay"

Figure 8: The cost-effectiveness acceptability curves for Raloxifene, women aged 60yrs.

CEACs for Raloxifene, 60yr olds. "Single-risk" population

Figure 9: The cost-effectiveness acceptability curves for Raloxifene, women aged 70yrs.

**Figure 10: The cost-effectiveness acceptability curves for Raloxifene, women aged 80yrs.**

Figure 11:

Figure 11: The contribution of breast cancer benefits to the total QALYs gained for Raloxifene 50yr olds. "Double-risk" population

Figure 12:

Figure 12: The contribution of breast cancer, CVD and fracture benefits to total QALYs gained for Raloxifene. "Double-risk" population.

**Figure 13: The cost-effectiveness acceptability curves for Raloxifene, women aged 50yrs**.

**Figure 14: The cost-effectiveness acceptability curves for Raloxifene, women aged 60yrs**.

**Figure 15: The cost-effectiveness acceptability curves for Raloxifene, women aged 70yrs**.

Figure 16: The cost-effectiveness acceptability curves for Raloxifene, women aged 80yrs.